TD Cowen keeps USD 15.00 target for Senseonics stock

Published on 10/15/2026 at 21:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 14.48 million, up 117.78 percent year over year. Senseonics stock costs EUR 7.25 on October 15, 2026.

Analyst view and upcoming results

TD Cowen maintained its USD 15.00 target on September 21, 2026.
Second-quarter revenue reached USD 14.48 million, up 117.78 percent year over year.
Senseonics stock costs EUR 7.25 at Lang & Schwarz on October 15, 2026 at 9:00 p.m. CEST.
Senseonics is scheduled to report its next results on November 4, 2026.

SENS, US81727U3032, Illustration mit AI erstellt.

TD Cowen maintained a Buy rating and a USD 15.00 price target for Senseonics Holdings on September 21, 2026, according to Investing.com. Against the USD 8.14 primary-exchange price on October 15, 2026, the target stands 45.73 percent higher. The euro quote was EUR 7.25 at Lang & Schwarz on October 15, 2026 at 9:00 p.m. CEST.

Revenue reached USD 14.48 million

Senseonics reported USD 14.48 million in second-quarter revenue for the period ended June 30, 2026, compared with USD 6.65 million in the second quarter of 2025. That represents growth of 117.78 percent year over year. The company recorded a net loss of USD 36.71 million, or USD 0.63 per diluted share, in the latest quarter, according to its earnings-call transcript published by Yahoo Finance.

Price stays below the target

The primary Nasdaq quote was USD 8.14 on October 15, 2026 at 3:03 p.m. EDT. The stock's 52-week range was USD 4.79 to USD 10.64, placing the latest home-market price 23.50 percent below the high. Trading volume reached 409,099 shares against an average of 681,001 shares on the same date.

Valuation and reporting date

Senseonics had a market capitalization of USD 430.5 million and a negative trailing price-to-earnings ratio of 3.59 on October 15, 2026. The company is scheduled to report its next results on November 4, 2026, according to ToAlpha.

Comparison with peers

SENS (Nasdaq, USD): P/E minus 3.59, market capitalization USD 430.5 million.

DexCom (Nasdaq, USD): plus 3.70 percent, P/E 34.16, market capitalization USD 32.7 billion.

Insulet (Nasdaq, USD): plus 3.20 percent, P/E 25.81, market capitalization USD 9.6 billion.

Senseonics had announced a strategic partnership with Beta Bionics on September 14, 2026, to integrate Eversense 365 with the iLet Bionic Pancreas, according to the company's investor-relations page.

The euro quote after hours

Senseonics develops implantable continuous glucose monitoring systems, with Eversense and Eversense XL designed for sensor wear of up to 90 and 180 days. The current euro indication is therefore best read alongside the company's operating trajectory: quarterly revenue accelerated sharply, while the latest loss shows that commercialization and product development still require substantial investment.

The further course of trading is shown by the continuously updated real-time quote of Senseonics stock.